{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:24:55Z","timestamp":1779200695811,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,17]]},"DOI":"10.7759\/cureus.97103","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:14:11Z","timestamp":1763421251000},"source":"Crossref","is-referenced-by-count":1,"title":["Neuroprotective Potential of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Type 2 Diabetes: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Rupanshu","family":"R","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajaybir S","family":"Buttar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. Dementia. (2017). https:\/\/www.who.int\/news\/item\/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis","volume":"82","author":"Seminer A","year":"2025","unstructured":"Seminer A, Mulihano A, O'Brien C, et al.. Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. JAMA Neurol. 2025, 82:450-60. 10.1001\/jamaneurol.2025.0360","journal-title":"JAMA Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2024.06.030","article-title":"Association between SGLT2 inhibitors and risk of dementia and Parkinson\u2019s disease: a meta-analysis of 12 randomized controlled trials","volume":"137","author":"Jaiswal V","year":"2024","unstructured":"Jaiswal V, Mashkoor Y, Raj N, Rajak K, Jaiswal A, Fonarow GC. Association between SGLT2 inhibitors and risk of dementia and Parkinson\u2019s disease: a meta-analysis of 12 randomized controlled trials. Am J Med. 2024, 137:1136-41. 10.1016\/j.amjmed.2024.06.030","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112430","article-title":"Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany","volume":"229","author":"Sarabhai T","year":"2025","unstructured":"Sarabhai T, Zingel R, Bohlken J, Kostev K. Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany. Diabetes Res Clin Pract. 2025, 229:112430. 10.1016\/j.diabres.2025.112430","journal-title":"Diabetes Res Clin Pract"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108276","article-title":"Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study","volume":"34","author":"Chiang PC","year":"2025","unstructured":"Chiang PC, Hsieh CY, Sung SF. Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study. J Stroke Cerebrovasc Dis. 2025, 34:108276.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu CY","year":"2023","unstructured":"Wu CY, Iskander C, Wang C, et al.. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care. 2023, 46:297-304. 10.2337\/dc22-1705","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112197","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a five-year retrospective cohort analysis of 160,752 patients","volume":"224","author":"Liu TH","year":"2025","unstructured":"Liu TH, Lin YM, Yu T, Wu JY, Lai CC. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a five-year retrospective cohort analysis of 160,752 patients. Diabetes Res Clin Pract. 2025, 224:112197. 10.1016\/j.diabres.2025.112197","journal-title":"Diabetes Res Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.223","article-title":"Co151 Association of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists with the risk of developing dementia in people with type 2 diabetes mellitus","volume":"26","author":"Wang J","year":"2023","unstructured":"Wang J, Toulis K, Gokhale K, et al.. Co151 Association of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists with the risk of developing dementia in people with type 2 diabetes mellitus. Value Health. 2023, 26:41-2. 10.1016\/j.jval.2023.09.223","journal-title":"Value Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14048","article-title":"Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: a population-based cohort study","volume":"20","author":"Tang H","year":"2024","unstructured":"Tang H, Donahoo WT, Svensson M, et al.. Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: a population-based cohort study. Alzheimers Dement. 2024, 20:5528-39. 10.1002\/alz.14048","journal-title":"Alzheimers Dement"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study","volume":"19","author":"Siao WZ","year":"2022","unstructured":"Siao WZ, Lin TK, Huang JY, Tsai CF, Jong GP. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study. Diab Vasc Dis Res. 2022, 19:14791641221098168. 10.1177\/14791641221098168","journal-title":"Diab Vasc Dis Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3220","article-title":"Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study","volume":"177","author":"Hong B","year":"2024","unstructured":"Hong B, Bea S, Ko HY, Kim WJ, Cho YM, Shin JY. Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study. Ann Intern Med. 2024, 177:1319-29. 10.7326\/M23-3220","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101655","article-title":"Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes","volume":"51","author":"Sun M","year":"2025","unstructured":"Sun M, Wang X, Lu Z, et al.. Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes. Diabetes Metab. 2025, 51:101655. 10.1016\/j.diabet.2025.101655","journal-title":"Diabetes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251317495","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on nervous system disorders: a systematic review and meta-analysis","volume":"59","author":"Xu B","year":"2025","unstructured":"Xu B, Yang M, Li S, Kang B, Zhou J. Effects of sodium-glucose cotransporter 2 inhibitors on nervous system disorders: a systematic review and meta-analysis. Ann Pharmacother. 2025, 59:809-21. 10.1177\/10600280251317495","journal-title":"Ann Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14306","article-title":"Sodium-glucose cotransporter\u20092 inhibition through henagliflozin ameliorates cognitive impairment in patients with type\u20092 diabetes","volume":"15","author":"Zhang S","year":"2024","unstructured":"Zhang S, Wang F, Xie L, et al.. Sodium-glucose cotransporter\u20092 inhibition through henagliflozin ameliorates cognitive impairment in patients with type\u20092 diabetes. J Diabetes Investig. 2024, 15:1596-603. 10.1111\/jdi.14306","journal-title":"J Diabetes Investig"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2064","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study","volume":"45","author":"Cheng H","year":"2022","unstructured":"Cheng H, Zhang Z, Zhang B, et al.. Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study. Diabetes Care. 2022, 45:1201-10. 10.2337\/dc21-2064","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01824-9","article-title":"Neuroinflammation and metabolic dysregulation as predictors of cognitive impairment, depression, and quality of life in type 2 diabetes mellitus patients on SGLT2 inhibitors and sulfonylureas","volume":"33","author":"Majid H","year":"2025","unstructured":"Majid H, Islam SU, Kohli S, Nidhi. Neuroinflammation and metabolic dysregulation as predictors of cognitive impairment, depression, and quality of life in type 2 diabetes mellitus patients on SGLT2 inhibitors and sulfonylureas. Inflammopharmacology. 2025, 33:4749-58. 10.1007\/s10787-025-01824-9","journal-title":"Inflammopharmacology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2024.101555","article-title":"The effect of sodium glucose co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients","volume":"26","author":"Nodirahon A","year":"2024","unstructured":"Nodirahon A, Majid H, Waghdhare S, Vohora D. The effect of sodium glucose co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients. Clin Epidemiol Glob Health. 2024, 26:101555. 10.1016\/j.cegh.2024.101555","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123001","article-title":"Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges","volume":"355","author":"Tran J","year":"2024","unstructured":"Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS. Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges. Life Sci. 2024, 355:123001. 10.1016\/j.lfs.2024.123001","journal-title":"Life Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06341-7","article-title":"Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice","volume":"240","author":"Pi\u0105tkowska-Chmiel I","year":"2023","unstructured":"Pi\u0105tkowska-Chmiel I, Herbet M, Gawro\u0144ska-Grzywacz M, Paw\u0142owski K, Ostrowska-Le\u015bko M, Dudka J. Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology (Berl). 2023, 240:983-1000. 10.1007\/s00213-023-06341-7","journal-title":"Psychopharmacology (Berl)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228767","article-title":"Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases","volume":"21","author":"Jensen NJ","year":"2020","unstructured":"Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020, 21:8767. 10.3390\/ijms21228767","journal-title":"Int J Mol Sci"},{"key":"ref21","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2023","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing, Treasure Island (FL), US; 2023."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei J","year":"2024","unstructured":"Mei J, Li Y, Niu L, et al.. SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Transl Neurodegener. 2024, 13:41. 10.1186\/s40035-024-00431-y","journal-title":"Transl Neurodegener"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/423698-neuroprotective-potential-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-type-2-diabetes-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:14:12Z","timestamp":1763421252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/423698-neuroprotective-potential-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-type-2-diabetes-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.97103","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}